[Quantitative rheographic study of the effects of a new drug combination: raubasine/dihydroergocristine].
D001783:Blood Flow Velocity; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004338:Drug Combinations; D004877:Ergoloid Mesylates / Q000627:therapeutic use*; D006801:Humans; D010992:Plethysmography, Impedance; D015016:Yohimbine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D004338:Drug Combinations; D004088:Dihydroergotoxine; D015016:Yohimbine; D004877:Ergoloid Mesylates
Etude rhéographique quantitative des effets d'une nouvelle association médicamenteuse: raubasine/dihydroergocristine